PAP
CRSP icon

Persistent Asset Partners’s CRISPR Therapeutics CRSP Stock Holding History

Persistent Asset Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-270
Closed -$2.72K – 838
2026
Q1 		$2.72K Buy
270
+12
+5% +$633 ﹤0.01% 300
2025
Q4 		$10.8K Hold
258
– – ﹤0.01% 323
2025
Q3 		$192K Hold
258
– – 0.13% 133
2025
Q2 		$73.4K Hold
258
– – 0.05% 136
2025
Q1 		$36.5K Buy
+258
New +$10.9K 0.03% 139

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Persistent Asset Partners's CRSP Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 218 shares worth $11.9K. The stake represents ﹤0.01% of the portfolio and ranks #690 among its holdings.

523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Persistent Asset Partners held 218 shares of CRISPR Therapeutics worth $11.9K as of Q2 2026.
  • CRISPR Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #690 holding.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.